Multiple Myeloma News and Research

RSS
Multiple myeloma is a cancer that begins in plasma cells, a type of white blood cell. These cells are part of your immune system, which helps protect the body from germs and other harmful substances. In time, myeloma cells collect in the bone marrow and in the solid parts of bone.
Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

New analysis confirms value of minimal residual disease as prognostic indicator in multiple myeloma

New analysis confirms value of minimal residual disease as prognostic indicator in multiple myeloma

FDA permits marketing of ClonoSEQ assay to detect minimal residual disease in blood cancer patients

FDA permits marketing of ClonoSEQ assay to detect minimal residual disease in blood cancer patients

Clinical trial investigators found non-compliant with requirement to report results on EU register

Clinical trial investigators found non-compliant with requirement to report results on EU register

New guidance for treatment of bone loss in hematologic stem cell transplant Recipients

New guidance for treatment of bone loss in hematologic stem cell transplant Recipients

Study gives new insights into how cells leverage GPCRs to control inflammation

Study gives new insights into how cells leverage GPCRs to control inflammation

New system accelerates discovery of chemical compounds that inhibit enzyme implicated in cancers

New system accelerates discovery of chemical compounds that inhibit enzyme implicated in cancers

Leukogene receives STTR grant to optimize compound for treatment-resistant multiple myeloma

Leukogene receives STTR grant to optimize compound for treatment-resistant multiple myeloma

Study yields therapeutic clues to combat drug resistance in rare aggressive cancer

Study yields therapeutic clues to combat drug resistance in rare aggressive cancer

NYU Langone's Perlmutter Cancer Center expands Blood and Marrow Transplant Program

NYU Langone's Perlmutter Cancer Center expands Blood and Marrow Transplant Program

NUS scientists develop new technology to customize optimal drug ‘cocktail’ for myeloma patients

NUS scientists develop new technology to customize optimal drug ‘cocktail’ for myeloma patients

FOXM1 contributes to treatment failure in acute myeloid leukemia

FOXM1 contributes to treatment failure in acute myeloid leukemia

New discovery could pave way for improved leukemia treatment

New discovery could pave way for improved leukemia treatment

RNA and DNA sequencing platform matches broader swath of drugs to late-stage cancer patients

RNA and DNA sequencing platform matches broader swath of drugs to late-stage cancer patients

Scientists solve 60-year-old mystery of how thalidomide caused birth defects

Scientists solve 60-year-old mystery of how thalidomide caused birth defects

Janssen’s Darzalex receives positive CHMP opinion for treating multiple myeloma patients

Janssen’s Darzalex receives positive CHMP opinion for treating multiple myeloma patients

CNDA approves KEYTRUDA for treatment of advanced melanoma

CNDA approves KEYTRUDA for treatment of advanced melanoma

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

AbbVie submits supplemental NDA to FDA for venetoclax to treat acute myeloid leukemia

AbbVie submits supplemental NDA to FDA for venetoclax to treat acute myeloid leukemia